Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Ottawa
$27,000.00
Investigation of the impact of (de)PARylation-based cancer therapies on muscle health in ovarian cancer-associated cachexia
FY 2025-26
Summary
Ovarian cancer (OC), the most lethal gynecological malignancy, will affect 1 in 68 Canadian women in their lifetime. An underrecognized complication of OC is cancer-associated cachexia, a wasting condition characterized by progressive skeletal muscle loss that worsens treatment response and survival outcomes. Although new preclinical OC models replicate the cachexia observed in patients, the biological mechanisms of muscle wasting in OC remain poorly understood. (de)PARylating therapies – including PARP inhibitors – have transformed outcomes for OC patients with Brca1/2 mutations, yet their effects on muscular health are unclear. Because (de)PARylation is implicated in DNA repair and energy metabolism, targeted therapies could unintentionally worsen tumour-induced muscle atrophy and impair regeneration. This project aims to test whether (de)PARylating therapies exacerbate OC-driven 1) muscle atrophy and 2) impaired regeneration. To model tumour-muscle communication, tumour-conditioned media will be applied to myotubes and isolated muscle fibers containing satellite cells (muscle stem cells) in the absence or presence of (de)PARylating therapies. Changes to myotube size, degradation-related gene expression, and metabolic function will be assessed as indicators of muscle atrophy, while changes to markers of satellite cell differentiation will be measured to evaluate impairments to regeneration. By clarifying how OC and targeted therapies influence muscle health, this work will provide insight into potential unintended effects of (de)PARylation therapies and guide safer treatment strategies to reduce the disease burden of OC in Canadian women.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
572963
Name
Rashid Mehreen
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigation of the impact of (de)PARylation-based cancer therapies on muscle health in ovarian cancer-associated cachexia
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cancer Cachexia; Muscle Atrophy; Muscle Regeneration; Ovarian Cancer; Parylation; Satellite Cells
Abstract
Ovarian cancer (OC), the most lethal gynecological malignancy, will affect 1 in 68 Canadian women in their lifetime. An underrecognized complication of OC is cancer-associated cachexia, a wasting condition characterized by progressive skeletal muscle loss that worsens treatment response and survival outcomes. Although new preclinical OC models replicate the cachexia observed in patients, the biological mechanisms of muscle wasting in OC remain poorly understood. (de)PARylating therapies – including PARP inhibitors – have transformed outcomes for OC patients with Brca1/2 mutations, yet their effects on muscular health are unclear. Because (de)PARylation is implicated in DNA repair and energy metabolism, targeted therapies could unintentionally worsen tumour-induced muscle atrophy and impair regeneration. This project aims to test whether (de)PARylating therapies exacerbate OC-driven 1) muscle atrophy and 2) impaired regeneration. To model tumour-muscle communication, tumour-conditioned media will be applied to myotubes and isolated muscle fibers containing satellite cells (muscle stem cells) in the absence or presence of (de)PARylating therapies. Changes to myotube size, degradation-related gene expression, and metabolic function will be assessed as indicators of muscle atrophy, while changes to markers of satellite cell differentiation will be measured to evaluate impairments to regeneration. By clarifying how OC and targeted therapies influence muscle health, this work will provide insight into potential unintended effects of (de)PARylation therapies and guide safer treatment strategies to reduce the disease burden of OC in Canadian women.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rashid, Mehreen
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~